Cerebrolysin CBL
Brain-derived peptide mixture
Porcine brain-derived mixture of low-molecular-weight peptides and amino acids, studied for neurotrophic and neuroprotective activity.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- Brain-derived peptide mixture
- Category
- Neuro, Cognitive & Sleep
- Type
- Single compound
- Abbreviation
- CBL
- Development and regulatory status
- Marketed drug in many countries; not FDA-approved
What researchers study
Porcine brain-derived preparation of low-molecular-weight peptides and amino acids, described as having neurotrophic and neuroprotective activity. Because it is a mixture, a single defined molecular mechanism is not established.
Research areas
- Neuroprotection and neurotrophic activity in neuronal models
- Acute ischaemic stroke clinical trials
- Vascular dementia clinical trials
- Cognitive-outcome and safety assessments
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- review
A 2023 Cochrane review of seven trials of Cerebrolysin or Cortexin (1,773 participants) found probably little or no difference in all-cause death in acute stroke
- review
A 2019 Cochrane update on vascular dementia assessed six randomised trials with 597 participants
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- SemaxAnother neurotrophic-pathway agent studied in cerebral ischaemia models
- P21 (P021)Neurotrophic peptide mimetic with overlapping neurotrophin-pathway research focus
